Literature DB >> 27481515

PKC iota promotes cellular proliferation by accelerated G1/S transition via interaction with CDK7 in esophageal squamous cell carcinoma.

Sujie Ni1, Lingling Chen2, Mei Li1, Weijuan Zhao2, Xiaohang Shan2, Miaomiao Wu2, Jialin Cheng1, Li Liang1, Yayun Wang2, Wenyan Jiang1, Jianguo Zhang3, Runzhou Ni4.   

Abstract

Protein kinase C iota (PKCι) has been shown to play an important role in tumorigenesis of many cancers. It was reported that frequent amplification and overexpression of PKCi were correlated with resistance to anoikis in primary esophageal squamous cell carcinomas (ESCC). In this study, we clarified a novel role of PKCι on the cell cycle progression and proliferation in ESCC. Western blot and immunohistochemistry (IHC) analysis showed that the expression of PKCι was higher in ESCC tumor tissues and cell lines. Meanwhile, IHC stain revealed that PKCι was positively correlated with clinical pathologic variables such as tumor size, tumor grade, and tumor invasion, as well as ki67. Immunoprecipitation and immunofluorescence assay revealed that PKCι/CDK7 has the physical interaction and were co-located in the cell nucleus. And this direct interaction could increase the phosphorylation level of CDK7. In vitro studies such as starvation and refeeding assay along with PKCι-shRNA transfection assay demonstrated that PKCι expression promoted proliferation of ESCC cells. And knocking PKCi down by silencing RNA (siRNA) significantly caused cell cycle arrest at G0/G1 phase, decreased rate of colony formation, and alleviated cellular apoptosis. This research provide new insights into PKCi signaling to more deeply understand its cancer-promoting function in ESCC.

Entities:  

Keywords:  CDK7; Cell cycle; Esophageal squamous cell carcinoma; PKCι; Proliferation

Mesh:

Substances:

Year:  2016        PMID: 27481515     DOI: 10.1007/s13277-016-5193-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  22 in total

1.  Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer.

Authors:  You Wang; Yingying Wang; Jingying Xiang; Fang Ji; Yan Deng; Chunhui Tang; Shuyun Yang; Qinghua Xi; Rong Liu; Wen Di
Journal:  Cancer Lett       Date:  2013-09-07       Impact factor: 8.679

2.  Transhiatal esophagectomy: clinical experience and refinements.

Authors:  M B Orringer; B Marshall; M D Iannettoni
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

3.  Incomplete folding upon binding mediates Cdk4/cyclin D complex activation by tyrosine phosphorylation of inhibitor p27 protein.

Authors:  Li Ou; Antonio M Ferreira; Steve Otieno; Limin Xiao; Donald Bashford; Richard W Kriwacki
Journal:  J Biol Chem       Date:  2011-06-29       Impact factor: 5.157

4.  Fission yeast Cdk7 controls gene expression through both its CAK and C-terminal domain kinase activities.

Authors:  Maxime Devos; Elise Mommaerts; Valerie Migeot; Harm van Bakel; Damien Hermand
Journal:  Mol Cell Biol       Date:  2015-02-17       Impact factor: 4.272

5.  Regulation of Cdk7 activity through a phosphatidylinositol (3)-kinase/PKC-ι-mediated signaling cascade in glioblastoma.

Authors:  Shraddha R Desai; Prajit P Pillai; Rekha S Patel; Andrea N McCray; Hla Y Win-Piazza; Mildred E Acevedo-Duncan
Journal:  Carcinogenesis       Date:  2011-10-21       Impact factor: 4.944

6.  The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma.

Authors:  Verline Justilien; Michael P Walsh; Syed A Ali; E Aubrey Thompson; Nicole R Murray; Alan P Fields
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

7.  Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover.

Authors:  A Kishimoto; Y Takai; T Mori; U Kikkawa; Y Nishizuka
Journal:  J Biol Chem       Date:  1980-03-25       Impact factor: 5.157

8.  Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration.

Authors:  Yuchan Wang; Fang Liu; Feng Mao; Qinlei Hang; Xiaodong Huang; Song He; Yingying Wang; Chun Cheng; Huijie Wang; Guangfei Xu; Tianyi Zhang; Aiguo Shen
Journal:  J Biol Chem       Date:  2013-02-07       Impact factor: 5.157

9.  Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities.

Authors:  Jorge Franco; Uthra Balaji; Elizaveta Freinkman; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Cell Rep       Date:  2016-01-21       Impact factor: 9.423

10.  Association between the Cyclin D1 G870A polymorphism and the susceptibility to and prognosis of upper aerodigestive tract squamous cell carcinomas: an updated meta-analysis.

Authors:  Yichen Meng; Chenglin Zhang; Xuhui Zhou
Journal:  Onco Targets Ther       Date:  2016-01-19       Impact factor: 4.147

View more
  4 in total

1.  Functional interaction of PkcA and PldB regulate aggregation and development in Dictyostelium discoideum.

Authors:  Sean Singh; Wasima Mohamed; Annelie Aguessy; Ella Dyett; Shriraj Shah; Mohammedasad Khan; Ramamurthy Baskar; Derrick Brazill
Journal:  Cell Signal       Date:  2017-02-28       Impact factor: 4.315

Review 2.  Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes.

Authors:  Nair Lopes; Margareta P Correia; Rui Henrique; Carmen Jerónimo
Journal:  Int J Mol Sci       Date:  2020-05-15       Impact factor: 5.923

Review 3.  CDK7 inhibitors as anticancer drugs.

Authors:  Georgina P Sava; Hailing Fan; R Charles Coombes; Lakjaya Buluwela; Simak Ali
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

4.  How to Make a Rodent Giant: Genomic Basis and Tradeoffs of Gigantism in the Capybara, the World's Largest Rodent.

Authors:  Santiago Herrera-Álvarez; Elinor Karlsson; Oliver A Ryder; Kerstin Lindblad-Toh; Andrew J Crawford
Journal:  Mol Biol Evol       Date:  2021-05-04       Impact factor: 16.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.